多替拉韦联合拉米夫定初始治疗HIV-1 RNA<500000拷贝/mL的48周结果
ACTG 5353研究评估多替拉韦联合拉米夫定初始治疗HIV-1感染的48周疗效与安全性。
要点
- 多替拉韦联合拉米夫定初始治疗48周病毒学成功率达85%。
- 无新耐药突变,研究相关3级及以上不良事件发生率5%。
研究设计与样本
- ACTG 5353研究,纳入120例 eligible 受试者,评估48周疗效与安全性。
主要发现
- 48周时102/120例(85%;95%CI 77%-91%)达病毒学成功(HIV-1 RNA<50拷贝/mL,FDA Snapshot标准)。
- 6例(5%)病毒学非成功,另1例在研究期间但未接受研究治疗时发生病毒学失败。
- 未观察到新耐药突变。
- 6例(5%)发生研究相关3级及以上不良事件,无人因不良事件终止研究治疗。
关键数值与推荐
- 病毒学成功定义为HIV-1 RNA<50拷贝/mL(FDA Snapshot标准)。
- 病毒学失败定义为第24周或之后确认HIV-1 RNA>200拷贝/mL。
- 病毒学成功比例采用双侧精确Clopper-Pearson 95%CI估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The AIDS Clinical Trials Group study A5353 demonstrated the efficacy and safety of dolutegravir and lamivudine for initial treatment of HIV-1 infection at week 24 in individuals with HIV-1 RNA 1000-500 000 copies/mL. Optimal ART for treatment-naive individuals must be durable. OBJECTIVES: The aim of this study was to estimate the efficacy and safety of dolutegravir plus lamivudine at week 48 and compare the efficacy in participants with baseline HIV-1 RNA ≤100 000 copies/mL versus >100 000 copies/mL. METHODS: Virological success was defined as HIV-1 RNA <50 copies/mL by FDA Snapshot criteria. Definition of virological failure included confirmed HIV-1 RNA >200 copies/mL at week 24 or later. The proportion of participants with virological success was estimated using two-sided exact Clopper-Pearson 95% CI. Comparison between screening HIV-1 RNA (≤100 000 versus >100 000 copies/mL) strata was carried out by Fisher's exact test. The study was registered with ClinicalTrials.gov, number NCT02582684. RESULTS: A total of 120 enrolled eligible participants were included in the analysis. At week 48, 102 of the 120 participants (85%; 95% CI 77%-91%) had virological success. Virological success was similar between screening HIV-1 RNA groups. Six (5%) participants had virological non-success and one additional participant experienced virological failure while on study but off study treatment. No new drug resistance mutations were observed. Six (5%) participants had study-related grade 3 or higher adverse events and none discontinued study treatment. CONCLUSIONS: These results add to the evidence that dolutegravir plus lamivudine is a safe and effective option for initial ART in individuals with HIV-1 RNA <500 000 copies/mL.
引用
- Nyaku AN, Zheng L, Gulick RM, et al. Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353. J Antimicrob Chemother. 2019. PMID: 30668695. doi:10.1093/jac/dky564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。